In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A | Zendy

Chunfu Wang | Zendy; Lourdes Valera | Zendy; Lingling Jia | Zendy; Melissa Kirk | Zendy; Min Gao | Zendy; Robert A. Fridell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A

Author(s) -

Chunfu Wang,

Lourdes Valera,

Lingling Jia,

Melissa Kirk,

Min Gao,

Robert A. Fridell

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01874-12

Subject(s) - daclatasvir , ns5a , virology , genotype , hepatitis c virus , in vitro , biology , hepacivirus , medicine , virus , genetics , ribavirin , gene

The NS5A replication complex inhibitor daclatasvir (DCV; BMS-790052) inhibits hybrid replicons containing hepatitis C virus (HCV) genotype 3a (HCV3a) NS5A genes with 50% effective concentrations (EC(50)s) ranging from 120 to 870 pM. Selection studies with a hybrid HCV3a replicon identified NS5A residues 31 and 93 as sites for DCV-selected resistance. Our results support the potential use of DCV as a component in combination therapies for HCV3a chronic infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research